Klin Farmakol Farm. 2018;32(1):20-21 | DOI: 10.36290/far.2018.004

Renoprotective effects of gliflozins

Jan Vachek, Vladimír Tesař

Klinika nefrologie 1. LF UK a VFN v Praze

Cardiovascular diseases are the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Theirlikelihood is further increased by the presence of diabetic kidney disease which develops in up to 40% of patients with T2DM.In the EMPA REG OUTCOME trial, which was a large randomized, placebo-controlled study, empagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT-2), was shown to have an effect on cardiovascular morbidity and mortality and on exacerbationof nephropathy; the study included patients with a high risk of cardiovascular events. Recently, cardio- and nephroprotectiveeffects have also been demonstrated in canagliflozin. Several mechanisms of nephroprotective action have been suggested,e.g. restoration of tubuloglomerular feedback, decrease in intraglomerular pressure, reduction in blood pressure, positive bodyweight change, or prevention of hyperglycaemia-induced tubular injury by changes in mitochondrial processes. In the very nearfuture, further data from studies in “real-life” conditions can be expected as well as data on the safety and efficacy of the individualagents in this promising drug group.

Keywords: empagliflozin, canagliflozin, diabetes mellitus, cardiovascular morbidity and mortality, renoprotectivity

Published: May 31, 2018  Show citation